Fig. 7: The effect of different treatment combinations on murine HGS2 omental tumours.
From: Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
A–C Bulk RNAseq was conducted on tumours from the time-point experiment in Fig. 6C. A Differentially enriched pathways in mice treated with CT plus anti-stab1 antibody compared to CT alone using Fgsea (n = 3 mice per group), P < 0.05 was considered significant. B Differentially enriched pathways in CT plus Foxp3-ASO compared to CT using Fgsea (n = 5 for CT plus Foxp3-ASO and 3 mice for CT), p < 0.05 was considered significant. C Differentially enriched pathways in the triple combination (CT plus Foxp3-ASO and anti-stab1 antibody) compared to CT plus Foxp3-ASO using Fgsea (n = 5 for the triple combination therapy and n = 5 for CT plus Foxp3-ASO) p < 0.05 was significant. D Representative IHC images for FOXP3 staining in HGS2 mouse omental tumours (scale bar at 200 μm). E Positive cells per mm2 for immune infiltrate in different treatment arms in the time-point shown experiment in Fig. 6C (n = 3–5 mice in each group). Error bar at median and 95%CI. Two-sided unpaired student t-test (+/− welch correction).
